AI Article Synopsis
- Sharing data from control groups in similar clinical trials can improve efficiency in drug development.
- There are both potential benefits, like increased data availability, and risks, such as privacy concerns related to data sharing.
- The article explores these aspects to highlight how effective data-sharing plans can impact concurrent randomized trials.
Article Abstract
Sharing data from control groups across concurrent randomised clinical trials with identical enrolment criteria and the same control therapy can translate into efficiencies for the drug development process. We discuss potential benefits and risks of prospective data-sharing plans for concurrent randomised trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925400 | PMC |
| http://dx.doi.org/10.1016/j.ejca.2022.11.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Behaviour change interventions to improve household sanitation and hygiene practices in urban settings: A systematic scoping review.
Int J Hyg Environ Health
January 2025
Department of Disease Control, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Introduction: Behaviour change interventions have the potential to improve sanitation and hygiene practices in urban settings. However, evidence on which behaviour change interventions have successfully improved sanitation and hygiene practices in urban settings is unclear.
Methods: We performed electronic searches across five databases and one grey literature database to identify relevant studies published between January 1, 1990 and November 20, 2023 in English.
Evidence-based Interventions for Youth With Concurrent Mental Health and Substance Use Disorders: A Scoping Review: Interventions fondées sur des données probantes pour les jeunes atteints de troubles concomitants de santé mentale et liés à l'usage de substances psychoactives : une étude de la portée.
Can J Psychiatry
January 2025
Department of Psychiatry, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Background: Mental health and substance use disorders typically onset during youth and commonly co-occur. Integrated treatment of two or more co-existing mental health and substance use disorders (i.e.
View Article and Find Full Text PDFUtilizing liquid-liquid biopolymer regulators to predict the prognosis and drug sensitivity of hepatocellular carcinoma.
Biol Direct
January 2025
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China.
Background: Liquid-liquid phase separation (LLPS) is essential for the formation of membraneless organelles and significantly influences cellular compartmentalization, chromatin remodeling, and gene regulation. Previous research has highlighted the critical function of liquid-liquid biopolymers in the development of hepatocellular carcinoma (HCC).
Methods: This study conducted a comprehensive review of 3,685 liquid-liquid biopolymer regulators, leading to the development of a LLPS related Prognostic Risk Score (LPRS) for HCC through bootstrap-based univariate Cox, Random Survival Forest (RSF), and LASSO analyses.
Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial.
Nat Med
January 2025
Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Radiotherapy displays unique antitumor synergism with immune checkpoint inhibitors, which is indicated by high pathological complete response (pCR) rates from single-arm trials of locally advanced rectal cancer (LARC). Here we test the efficacy and safety of the radiation-immune checkpoint inhibitor combination in patients with LARC in a phase 2, randomized trial conducted in eight major colorectal cancer centers in Beijing. In total, 186 eligible all-comer (proficient mismatch repair and deficient mismatch repair) participants were enrolled.
View Article and Find Full Text PDFHome high-flow therapy during recovery from severe chronic obstructive pulmonary disease (COPD) exacerbation: a mixed-methods feasibility randomised control trial.
BMJ Open Respir Res
January 2025
Lane Fox Clinical Respiratory Physiology Research Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Introduction: Patients recovering from severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) have a 30-day readmission rate of 20%. This study evaluated the feasibility of conducting a randomised controlled trial to evaluate clinical, patient-reported and physiological effects of home high-flow therapy (HFT) in addition to usual medical therapy, in eucapnic patients recovering from AECOPD to support the design of a phase 3 trial.
Methods: A mixed-methods feasibility randomised controlled trial (quantitative primacy, concurrently embedded qualitative evaluation) (ISRCTN15949009) recruiting consecutive non-obese patients hospitalised with AECOPD not requiring acute non-invasive ventilation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!